文献速递肝病

沉默TGF-β2靶向胆汁淤积性肝病

TGF-β2 silencing to target biliary-derived liver diseases.
PubMed 文献 · Gut · 2020-01-28

研究在MDR2-KO小鼠中评估TGF-β2反义寡核苷酸(AON)对胆汁淤积性肝病纤维化和炎症的影响,发现AON治疗减少胶原沉积和纤维化基因表达,且对健康肝脏无不良影响,提示靶向TGF-β2可用于早期胆汁淤积性肝病。

要点

  • TGF-β2在PSC和PBC患者肝组织中表达上调,与CD45表达正相关。
  • MDR2-KO小鼠中TGF-β2 AON治疗减少纤维化,无健康肝脏不良反应。
  • TGF-β2沉默调节炎症基因表达并增加F4/80阳性细胞浸润。

核心结论

  • 沉默TGF-β2可改善MDR2-KO小鼠的肝纤维化,为靶向TGF-β2的药物开发提供依据。

研究设计与样本

  • 使用MDR2-KO小鼠(人类胆汁淤积性肝病模型)进行TGF-β2反义寡核苷酸(AON)干预研究。
  • 在分子、细胞和组织水平分析TGF-β2沉默对纤维化和炎症微环境的影响。

主要发现

  • TGF-β2诱导胆管细胞和肝星状细胞中纤维化基因表达。
  • MDR2-KO小鼠中AON治疗降低胶原沉积、羟脯氨酸含量和αSMA表达,诱导PparG表达,显著减少纤维化且对健康肝脏无不良影响。
  • AON治疗调节Ccl3、Ccl4、Ccl5、Mki67和Notch3表达,增加F4/80阳性细胞(包括嗜酸性粒细胞)浸润,减少CD45阳性炎症细胞数量。
  • PSC/PBC患者中TGFB2与CD45表达正相关,且定位于病变肝组织的相似区域。

临床怎么用

  • TGF-β2可能成为早期胆汁淤积性肝病(如PSC和PBC)的潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: TGF-β2 (TGF-β, transforming growth factor beta), the less-investigated sibling of TGF-β1, is deregulated in rodent and human liver diseases. Former data from bile duct ligated and MDR2 knockout (KO) mouse models for human cholestatic liver disease suggested an involvement of TGF-β2 in biliary-derived liver diseases. DESIGN: As we also found upregulated TGFB2 in liver tissue of patients with primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), we now fathomed the positive prospects of targeting TGF-β2 in early stage biliary liver disease using the MDR2-KO mice. Specifically, the influence of TgfB2 silencing on the fibrotic and inflammatory niche was analysed on molecular, cellular and tissue levels. RESULTS: TgfB2-induced expression of fibrotic genes in cholangiocytes and hepatic stellate cellswas detected. TgfB2 expression in MDR2-KO mice was blunted using TgfB2-directed antisense oligonucleotides (AON). Upon AON treatment, reduced collagen deposition, hydroxyproline content and αSMA expression as well as induced PparG expression reflected a significant reduction of fibrogenesis without adverse effects on healthy livers. Expression analyses of fibrotic and inflammatory genes revealed AON-specific regulatory effects on Ccl3, Ccl4, Ccl5, Mki67 and Notch3 expression. Further, AON treatment of MDR2-KO mice increased tissue infiltration by F4/80-positive cells including eosinophils, whereas the number of CD45-positive inflammatory cells decreased. In line, TGFB2 and CD45 expression correlated positively in PSC/PBC patients and localised in similar areas of the diseased liver tissue. CONCLUSIONS: Taken together, our data suggest a new mechanistic explanation for amelioration of fibrogenesis by TGF-β2 silencing and provide a direct rationale for TGF-β2-directed drug development.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Dropmann A, Dooley S, Dewidar B, et al. TGF-β2 silencing to target biliary-derived liver diseases. Gut. 2020. PMID: 31992593. doi:10.1136/gutjnl-2019-319091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。